Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer

Castration Resistant ◽

CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent

Annals of Oncology ◽

10.1093/annonc/mdw372.50 ◽

2016 ◽

Vol 27 ◽

pp. vi262

Author(s):

R. de Wit ◽

K. Fizazi ◽

E. Efstathiou ◽

R. Dittamore ◽

S. Hitier ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Castration Resistant ◽

MP52-12 COMPARISON OF ALTERNATIVE ANDROGEN RECEPTOR-AXIS-TARGETED AGENT (ARATA) VERSUS DOCETAXEL AS SECOND-LINE THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER INITIAL ARATA IN REAL-WORLD CLINICAL PRACTICE IN JAPAN

The Journal of Urology ◽

10.1016/j.juro.2018.02.1663 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Yuto Matsushita ◽

Keita Tamura ◽

Takayuki Sugiyama ◽

Hideaki Miyake

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Androgen Receptor ◽

Real World ◽

Second Line ◽

Second Line Therapy ◽

Castration Resistant ◽

Line Therapy ◽

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

Journal of Bone Oncology ◽

10.1016/j.jbo.2021.100388 ◽

2021 ◽

Vol 30 ◽

pp. 100388 ◽

Cited By ~ 1

Author(s):

Mark Clemons ◽

Michelle Liu ◽

Carol Stober ◽

Gregory Pond ◽

Mashari Jemaan Alzahrani ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Castration Resistant ◽

Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.07.016 ◽

2017 ◽

Vol 15 (6) ◽

pp. e1073-e1080 ◽

Cited By ~ 8

Author(s):

Nobuaki Matsubara ◽

Yoko Yamada ◽

Ken-ichi Tabata ◽

Takefumi Satoh ◽

Naoto Kamiya ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Sequential Treatment ◽

Castration Resistant ◽

Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.11.007 ◽

2018 ◽

Vol 16 (3) ◽

pp. 219-225 ◽

Cited By ~ 7

Author(s):

Hideaki Miyake ◽

Takayuki Sugiyama ◽

Ryota Aki ◽

Yuto Matsushita ◽

Keita Tamura ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Practice ◽

Androgen Receptor ◽

Real World ◽

Second Line ◽

Second Line Therapy ◽

Castration Resistant ◽

Line Therapy ◽

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2018.08.002 ◽

2018 ◽

Vol 36 (11) ◽

pp. 500.e1-500.e9 ◽

Cited By ~ 11

Author(s):

William K. Oh ◽

Wendy Y. Cheng ◽

Raymond Miao ◽

Francis Vekeman ◽

Marjolaine Gauthier-Loiselle ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Second Line ◽

First Line ◽

Castration Resistant ◽

Community Oncology ◽

Early Progression ◽

Targeted Agent ◽

Line Chemotherapy

587P Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1100 ◽

2021 ◽

Vol 32 ◽

pp. S636-S637

Author(s):

A.K. Morgans ◽

T.E. Hutson ◽

A.K. Guan ◽

D. Garcia ◽

A. Zhou ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Castration Resistant ◽

Cost Impact ◽

Targeted Agent ◽

Previously Treated

Neuroendocrine secretory profiles are not associated with treatment response to Lu-177-PSMA-617 radioligand therapy in patients with advanced metastatic castration-resistant prostate cancer

10.1055/s-0040-1708342 ◽

2020 ◽

Author(s):

T Derlin ◽

R Werner ◽

C Henkenberens ◽

TL Ross ◽

FM Bengel

Keyword(s):

Prostate Cancer ◽

Treatment Response ◽

Radioligand Therapy ◽

Castration Resistant

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Prostate Specific Membrane Antigen ◽

Radioligand Therapy ◽

Castration Resistant ◽

Specific Membrane

New combination therapies for castration-resistant prostate cancer

Oncology Abstracts ◽

10.1530/oncolabs.1.p031 ◽

2019 ◽

Author(s):

Mitchell G Lawrence ◽

Laura H Porter ◽

Daisuke Obinata ◽

Shahneen Sandhu ◽

Luke A Selth ◽

...

Keyword(s):

Prostate Cancer ◽

New Combination ◽

Combination Therapies ◽

Castration Resistant